Research Signal – Source date 2021-02-22
A cost-effectiveness analysis does not ask only how much a treatment costs. It also compares that cost with the health benefit it is expected to provide. A dollar threshold supplies a benchmark for judging that tradeoff: the analysis’s conclusion depends in part on how much spending per added health benefit is considered acceptable. It is an analytical cutoff, not the drug’s price or a patient’s bill.
A 2021 systematic review gathered 28 US cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer (NSCLC). The studies did not all use the same benchmark. Their reported thresholds also differed by the type of organization funding the analysis, raising a practical question for anyone comparing published judgments of value: are the studies applying a similar yardstick?
The benchmark varied across sponsor groups
Every included study published after 2009 applied a threshold of at least $100,000. Among the studies, the median threshold was $150,000 for those supported by industry and $100,000 for those supported by nonprofit organizations. The industry-supported thresholds were also more spread out; the nonprofit-supported thresholds were more concentrated around their lower median.
A median describes the midpoint of a group’s reported values. It does not mean that every industry-supported analysis used $150,000, or that every nonprofit-supported analysis used $100,000. The review’s comparison describes the benchmarks used in the analyses. By itself, it does not show why a sponsor selected a particular threshold or establish that a different cutoff reversed the value verdict for any specific drug.
The difference matters because cost-effectiveness is a judgment made against a benchmark, rather than a stand-alone property like a medicine’s name or dose. Two analyses can therefore be difficult to compare if their assumptions and thresholds differ. The review identifies a sponsor-group pattern, but the aggregate figures do not reveal the role each benchmark played in any individual study’s conclusion.
A growing set of studies, with an uneven treatment mix
The evidence covered analyses published from 2008 through 2020, and 18 of the 28 appeared during 2017–2020. Fifteen focused on non-squamous NSCLC. The most frequently evaluated therapy was pembrolizumab, appearing in 11 studies, followed by bevacizumab in eight and erlotinib in four.
Those counts show which treatments and disease group featured most often in this body of economic research. They are not a ranking of clinical effectiveness, and they do not mean that the most frequently studied medicine offered the best value. The review brings together cost-effectiveness analyses; it is not a new treatment trial comparing patient outcomes.
The concentration of studies in recent years also sits alongside a changing set of medicines, increasingly directed at particular mutations. That makes the exact comparison important: an overall threshold pattern across studies cannot substitute for the specific clinical and economic evidence behind a decision about one treatment and one patient group.
What the aggregate figures leave unresolved
The review’s reported counts and medians provide a broad view of how US analyses set their benchmarks. They do not supply the individual economic estimates or study-level methods needed to judge a particular drug’s cost-effectiveness from these figures alone. The threshold medians cannot tell a reader whether a specific treatment’s added health benefit justified its added cost under a given analysis, or how sensitive that conclusion was to alternative assumptions.
Nor does the sponsor comparison explain its own causes. The greater spread in industry-supported thresholds is an observed pattern in the included analyses; it is not evidence that funding determined a study’s choice. To assess a treatment decision, readers would need the relevant study’s underlying comparison and methods, alongside clinical evidence. This review alone does not show that one therapy improves outcomes more than another.
How clearer cost comparisons could guide lung cancer spending
If future analyses make their thresholds and methods sufficiently comparable, US healthcare decision-makers could judge the value of mutation-specific and immune therapies more consistently when allocating treatment resources. That could make spending comparisons easier to interpret across studies, while treatment choices would still need to rest on clinical evidence as well as economic analysis.
Key Sources
- Primary source: Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review.
DOI or Journal Page · Review or Meta-Analysis · 2021-02-22
Keep exploring